AKT Inhibitors - Pipeline Insights 2018

PUBLISHED DATE : Feb 2018 | Pages : 70

Up to $600 off Untill Oct 2020

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

70 Pages

The serine/threonine kinase ‘AKT’, commonly known as protein kinase B or PKB, plays a vital role in regulating diverse cellular functions. AKT has three isoforms (AKT1, AKT2 and AKT3) which play a vital role in diverse cellular functions including cell size/growth, proliferation, survival, glucose metabolism, genome stability, transcription and protein synthesis, and neovascularization. A plethora of studies supports have proven that the AKT signaling cascade is frequently impaired in many types of cancers, including, breast, lung, gastric, ovary and pancreas. It is also proven to be associated with tumor aggressiveness. Thus AKT is considered as one a potent target candidate for cancer therapy. AKT inhibitors are targeted drug molecules that hold the potential to inhibit the activated form of AKT that leads to normal functioning of AKT kinases.

Research and development activity for AKT inhibitors is quite robust. Clinical experiments on investigational AKT molecules are focused on cancers including breast cancer, gastric cancer, prostate cancer, multiple myeloma. The AKT inhibitors pipeline has more than 20 molecules across various stages of clinical development which are likely to gain regulatory approval in foreseeable future. Few of the key pipeline AKT inhibitors include AT13148, SR13688, LY2780301, BAY 1125976, AZD5363, GSK690693, and A 443654. In pipeline analysis, these molecules are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage. Few of the key companies which are involved in the development of Akt inhibitors include Otsuka, Eli Lilly, Bayer, GSK, Merck, Novartis, Amgen, and AbbVie.

Reasons to Buy

  • To gain erudite insights about the AKT inhibitor pipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation
Read More

Select a license type that suits your business needs

Single User Licence
$1200.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$1600.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$2400.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$800.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Related Reports

20%

Off

FLASH DISCOUNT

DAYS

HOURS

MINUTES

SECONDS

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date